Our vision
No one should die of cancer
Over one-third of people in developed countries develop cancer and 8.2 million people die from cancer every year. Angiex is committed to being part of the solution to the problem.
Exploiting novel biology to gain revolutionary power over cancer
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality
Our vision
Our latest findings
Angiex, developer of Nuclear-Delivered Antibody- Drug Conjugate™ (ND-ADC) therapies for solid cancers, participated in the 13th Annual World ADC Meeting in San Diego, California. During the meeting, the company provided an overview of its technology and near-term plans for its lead asset, AGX101, in its poster “AGX101 – A novel TM4SF1-directed ADC for the treatment of all solid tumors.”
Our Science
Angiex’s Nuclear Delivery Platform™ delivers chemotherapeutic payloads to the nucleus of tumor cells and the endothelial cells of tumor blood vessels, offering the potential to create drugs for solid cancers with exceptional efficacy and therapeutic margin.
Angiex’s lead ND-ADC, AGX101, will soon be heading to the clinic, and a pipeline of additional ND-ADCs is in discovery-stage development. Angiex founders discovered VEGF-A and have been recognized as the world’s leading experts in tumor blood vessel biology.
